f) to assist with the implementation of Commonwealth Government policies and programs in cancer control g) to provide financial assistance, out of money appropriated by the Parliament, for research mentioned in paragraph (e) and for the implementation of policies and programs mentioned in paragraph (f ) h) any functions that the Minister, by writing, directs Cancer Australia to perform. Within this remit, Cancer Australia is funded by the Australian Government to deliver work in specific cancer types; priority cancer research; clinical protocol development; cancer data improvements; and a grant initiative to support people with cancer. Cancer Australia is responsible for implementation of the Australian Brain Cancer Mission, which aims to double survival rates and improve the quality of life of people living with brain cancer over the next ten years to 2027, with the longer term aim of defeating brain cancer. Cancer Australia’s total appropriation in 2018-19 is $30.971 million. Over the four years to 2021-22) of this plan, it is anticipated that the total appropriation for Cancer Australia will remain relatively stable. Australian Public Service wide initiatives require that Cancer Australia continuously consider efficiencies in how it operates. As a recognised small government agency the ongoing incorporation of efficiencies presents practical challenges. In response to these challenges, Cancer Australia has adopted continuous improvement processes and applies robust risk management processes. 4.0 Environment Cancer Australia operates in a complex and evolving environment with current and emerging challenges. Australia’s growing and ageing population will continue to future increases in cancer incidence and health service utilisation, while cancer care is becoming increasingly complex and costly, with the development of new treatments and technologies. Australia’s increasing expenditure on health highlights the importance of priority-driven investment in cancer control to guide the optimal use of available resources and enable the health system to be responsive to these and future challenges. Cancer Australia’s Corporate Plan 2018-19 has been developed within the context of this changing landscape for the reporting periods covered by this Plan (the financial years 2019-20, 2020-21 and 2021-22). Some of these specific trends and future challenges, and how Cancer Australia intends to achieve its purpose are captured below. Strategic outlook over the forward In Australia, cancer is a national health priority. In 2017, it was estimated that one in two people were at risk of being diagnosed with cancer by the age of 85 years. More people are being diagnosed with cancer and the incidence is projected to increase by 8.4 per cent to approximately 150,000, by 2020.
f) to assist with the implementation of Commonwealth Government policies and programs in cancer control g) to provide financial assistance, out of money appropriated by the Parliament, for research mentioned in paragraph (e) and for the implementation of policies and programs mentioned in paragraph (f ) h) any functions that the Minister, by writing, directs Cancer Australia to perform. Within this remit, Cancer Australia is funded by the Australian Government to deliver work in specific cancer types; priority cancer research; clinical protocol development; cancer data improvements; and a grant initiative to support people with cancer. Cancer Australia is responsible for implementation of the Australian Brain Cancer Mission, which aims to double survival rates and improve the quality of life of people living with brain cancer over the next ten years to 2027, with the longer term aim of defeating brain cancer. Cancer Australia’s total appropriation in 2018-19 is $30.971 million. Over the four years to 2021-22) of this plan, it is anticipated that the total appropriation for Cancer Australia will remain relatively stable. Australian Public Service wide initiatives require that Cancer Australia continuously consider efficiencies in how it operates. As a recognised small government agency the ongoing incorporation of efficiencies presents practical challenges. In response to these challenges, Cancer Australia has adopted continuous improvement processes and applies robust risk management processes. 4.0 Environment Cancer Australia operates in a complex and evolving environment with current and emerging challenges. Australia’s growing and ageing population will continue to future increases in cancer incidence and health service utilisation, while cancer care is becoming increasingly complex and costly, with the development of new treatments and technologies. Australia’s increasing expenditure on health highlights the importance of priority-driven investment in cancer control to guide the optimal use of available resources and enable the health system to be responsive to these and future challenges. Cancer Australia’s Corporate Plan 2018-19 has been developed within the context of this changing landscape for the reporting periods covered by this Plan (the financial years 2019-20, 2020-21 and 2021-22). Some of these specific trends and future challenges, and how Cancer Australia intends to achieve its purpose are captured below. Strategic outlook over the forward In Australia, cancer is a national health priority. In 2017, it was estimated that one in two people were at risk of being diagnosed with cancer by the age of 85 years. More people are being diagnosed with cancer and the incidence is projected to increase by 8.4 per cent to approximately 150,000, by 2020.
cancer-australia-corporate-plan-2018-19.docx